LOGO.png
Rafarma’s Global Pharmaceutical Strategy At A Glance
May 18, 2021 08:53 ET | RAFARMA PHARMACEUTICALS INC
Nicosia, Cyprus, May 18, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is an international biotechnological and pharmaceutical company that combines research centers and modern...
LOGO.jpg
Vivos Inc. Provides 2020 Recap and Outlines 2021 Objectives
January 28, 2021 09:30 ET | Vivos Inc.
Richland WA, Jan. 28, 2021 (GLOBE NEWSWIRE) --  Vivos Inc. (OTCQB: RDGL), provides 2020 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2021, I think it is...
Rise in Radioligand Therapies to Drive Global Radiopharmaceuticals Market till 2023: WiseGuyReports
June 11, 2019 09:09 ET | WiseGuy Research Consultants Pvt. Ltd.
Pune, India, June 11, 2019 (GLOBE NEWSWIRE) -- Radiopharmaceuticals are a group of compounds used for discerning the presence of abnormalities in tissues, organs, or cells. They are a vital...
logo long.jpg
Global Radiopharmaceuticals in Nuclear Medicine Market to Surpass US$ 10.6 Billion by 2026 – Coherent Market Insights
May 10, 2019 08:30 ET | CMI
SEATTLE, May 10, 2019 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global radiopharmaceuticals in nuclear medicine market was valued at US$ 4,986.4 million in 2017 and is projected to...
20170406 Telix Logo.png
GenesisCare and Telix Enter into Strategic Collaboration Agreement to Accelerate Patient Access to New Treatments
October 09, 2018 18:00 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and SYDNEY, Australia, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...
Curium enhances its
Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations
May 02, 2018 03:10 ET | Curium
Paris, May 02, 2018 (GLOBE NEWSWIRE) -- Curium has successfully completed its previously announced acquisition of the French commercial and manufacturing operations of Cyclopharma, a leading...
Telix_Main_Logo (3).png
Telix Pharmaceuticals Establishes Japanese Subsidiary, Appoints Key Executives
January 14, 2018 21:12 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO Japan, Jan. 15, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the...
Telix_Main_Logo (3).png
Telix Pharmaceuticals and JFE Announce Japanese Radiopharmaceutical Manufacturing Partnership
December 12, 2017 17:00 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and TOKYO, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development...
Telix_Main_Logo (3).png
Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange
November 14, 2017 20:00 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of...
Telix_Main_Logo (3).png
Telix Pharmaceuticals and CellSight Technologies Conclude Collaboration and License Agreement for VisAcT ImmunoPET Technology
September 19, 2017 21:46 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and SAN FRANCISCO, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company) is pleased to announce the conclusion of a collaboration and licensing...